Actelion expects flat 2013 earnings

Actelion Ltd. (SIX:ATLN) introduced 2013 guidance and said it expects to maintain core earnings in local currencies at 2012 levels, with single-digit core earnings growth in 2014 and double-digit growth by 2015. Core 2012 EPS was CHF3.69, up from CHF3.04 in 2011. The company also proposed a 25% larger annual dividend of CHF1.

Actelion reported 2012 total product sales of CHF1.72 billion ($1.88 billion), down 2% in local currencies from CHF1.71 billion ($1.87 billion) in 2011. Of that CHF1.71 billion, pulmonary arterial hypertension (PAH) drug Tracleer bosentan, accounted for CHF1.5 billion ($1.6 billion). Tracleer sales declined 4% in local currencies from 2011. ...